Registration openEarly bird rates available for the 2014 meeting of the International Workshop on Co-morbidities and Adverse Drug Reactions in HIV.
Most popular articleReview of drug interactions with telaprevir and antiretrovirals
2014 Subscriptions availableOrder the next volume of Antiviral Therapy today.
Editors-in-Chief: Douglas D Richman & Joep MA Lange
Antiviral Therapy (an official publication of the International Society of Antiviral Research) is an international, peer-reviewed journal devoted to publishing articles on the clinical development and use of antiviral agents and vaccines, and the treatment of all viral diseases. Antiviral Therapy is one of the leading journals in virology and infectious diseases (2012 ISI impact factor: 3.07).
The journal is comprehensive, and publishes articles concerning all clinical aspects of antiviral therapy. It features editorials, original research papers, specially commissioned review articles, letters and book reviews. The journal is aimed at physicians and specialists interested in clinical and basic research.
♦ Immediate online publication
♦ A leading Editorial Board ensuring high-quality standards
♦ Worldwide readership
♦ Inclusion in major indexing and abstracting services
♦ No page charges
Rimsky et al. report long-term resistance to rilpivirine in the ECHO/THRIVE Phase III trials. At 96 weeks, resistance patterns were consistent with 48-week data, and suggest most virological failures and resistance-associated mutations occur during the first year of treatment. Overall, the evidence demonstrates rilpivirine is non-inferior to existing therapies for HIV-infected, treatment-naive patients. Read more here.
The Editorial Office welcomes queries about publishing supplements within the journal. Please visit the Supplements page for more information.
ISSN: 1359-6535 (print); 2040-2058 (online)